Diagnostic Validity of Serum Macrophage Inhibitor Cytokine and Tissue Polypeptide-Specific Antigen in Pancreatobiliary Diseases

Özkan, Hasan; Demirbaş, Selma; İbi̇ş, Mehmet; Akbal, Erdem; Köklü, Seyfettin

doi:10.1159/000328963

Cited by 26 publications

(25 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They observed that the mean MIC-1 level in healthy controls, CP and PC was 0.76 ng/ml, 2.36 ng/ml and 5.4 ng/ml respectively. Further studies emphasized the diagnostic efficacy of MIC-1 equivalent to CA19-9 [6], [7]. In our study, the mean plasma MIC-1 levels in these patient groups were 1.5 ng/ml, 1.6 ng/ml and 4.5 ng/ml ( Table 2 ).…”

Section: Discussionsupporting

confidence: 51%

“…Further, Ozkan et al, observed significantly elevated expression of MIC-1 in PC cases in comparison to other pancreatobilary diseases and healthy controls. It was found to have similar sensitivity as that to CA19.9 (81%) in differentiating PC from other benign diseases [7]. Serum MIC-1 was found to outperform CA19-9 in CA19-9, in differentiating patients with resectable pancreatic cancer from controls [8], [9].…”

Section: Introductionmentioning

confidence: 76%

See 1 more Smart Citation

Potentials of Plasma NGAL and MIC-1 as Biomarker(s) in the Diagnosis of Lethal Pancreatic Cancer

et al. 2013

View full text Add to dashboard Cite

Pancreatic cancer (PC) is lethal malignancy with very high mortality rate. Absence of sensitive and specific marker(s) is one of the major factors for poor prognosis of PC patients. In pilot studies using small set of patients, secreted acute phase proteins neutrophil gelatinase associated lipocalin (NGAL) and TGF-β family member macrophage inhibitory cytokine-1 (MIC-1) are proposed as most potential biomarkers specifically elevated in the blood of PC patients. However, their performance as diagnostic markers for PC, particularly in pre-treatment patients, remains unknown. In order to evaluate the diagnostic efficacy of NGAL and MIC-1, their levels were measured in plasma samples from patients with pre-treatment PC patients (n = 91) and compared it with those in healthy control (HC) individuals (n = 24) and patients with chronic pancreatitis (CP, n = 23). The diagnostic performance of these two proteins was further compared with that of CA19-9, a tumor marker commonly used to follow PC progression. The levels of all three biomarkers were significantly higher in PC compared to HCs. The mean (± standard deviation, SD) plasma NGAL, CA19-9 and MIC-1 levels in PC patients was 111.1 ng/mL (2.2), 219.2 U/mL (7.8) and 4.5 ng/mL (4.1), respectively. In comparing resectable PC to healthy patients, all three biomarkers were found to have comparable sensitivities (between 64%-81%) but CA19-9 and NGAL had a higher specificity (92% and 88%, respectively). For distinguishing resectable PC from CP patients, CA19-9 and MIC-1 were most specific (74% and 78% respectively). CA19-9 at an optimal cut-off of 54.1 U/ml is highly specific in differentiating resectable (stage 1/2) pancreatic cancer patients from controls in comparison to its clinical cut-off (37.1 U/ml). Notably, the addition of MIC-1 to CA19-9 significantly improved the ability to distinguish resectable PC cases from CP (p = 0.029). Overall, MIC-1 in combination with CA19-9 improved the diagnostic accuracy of differentiating PC from CP and HCs.

show abstract

Section: Discussionsupporting

confidence: 51%

Section: Introductionmentioning

confidence: 76%

Potentials of Plasma NGAL and MIC-1 as Biomarker(s) in the Diagnosis of Lethal Pancreatic Cancer

et al. 2013

View full text Add to dashboard Cite

show abstract

“…[35–40] It was considered a good biomarker in discriminating pancreatic and other periampullary cancers. [41,42] However, the relationship between GDF-15 and AP has not been fully illustrated. Our study showed that GDF-15 was an independent marker in identifying severe AP, but the mechanism of GDF-15 in the progression of AP remains unclear and should be elucidated further.…”

Section: Discussionmentioning

confidence: 99%

Plasma cytokines can help to identify the development of severe acute pancreatitis on admission

Deng

Cai

et al. 2017

Medicine

View full text Add to dashboard Cite

show abstract

“…In colon cancer, serum levels were elevated in patients with premalignant colonic polyps, then rose progressively with the evolution of the disease to localized and finally metastatic cancer and predicted disease outcome (Brown et al, 2003) (Figure 4). Subsequent studies by many groups have demonstrated that broadly similar findings can be seen in most, if not all, malignancies, including those of the prostate (Welsh et al, 2003;Bauskin et al, 2005;Rasiah et al, 2006;Brown et al, 2006), breast (Welsh et al, 2003), pancreas (Koopmann et al, 2004;Grote and Logsdon, 2007;Ozkan et al, 2011), ovary (Bock et al, 2010;Staff et al, 2011), and lung (Lerner et al, 2016a).…”

Section: Mic-1/gdf15 Expressionmentioning

confidence: 91%

The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases

et al. 2018

View full text Add to dashboard Cite

MIC-1/GDF15 is a stress response cytokine and a distant member of the transforming growth factor beta (TGFb) superfamily, with no close relatives. It acts via a recently identified receptor called glial-derived neurotrophic factor (GDNF) receptor alpha-like (GFRAL), which is a distant orphan member of the GDNF receptor family that signals through the tyrosine kinase receptor Ret. MIC-1/GDF15 expression and serum levels rise in response to many stimuli that initiate cell stress and as part of a wide variety of disease processes, most prominently cancer and cardiovascular disease. The best documented actions of MIC-1/GDF15 are on regulation of energy homeostasis. When MIC-1/GDF15 serum levels are substantially elevated in diseases like cancer, it subverts a physiological pathway of appetite regulation to induce an anorexia/cachexia syndrome initiated by its actions on hindbrain neurons. These effects make it a potential target for the treatment of both obesity and anorexia/cachexia syndromes, disorders lacking any highly effective, readily accessible therapies.

show abstract

Diagnostic Validity of Serum Macrophage Inhibitor Cytokine and Tissue Polypeptide-Specific Antigen in Pancreatobiliary Diseases

Cited by 26 publications

References 24 publications

Potentials of Plasma NGAL and MIC-1 as Biomarker(s) in the Diagnosis of Lethal Pancreatic Cancer

Potentials of Plasma NGAL and MIC-1 as Biomarker(s) in the Diagnosis of Lethal Pancreatic Cancer

Plasma cytokines can help to identify the development of severe acute pancreatitis on admission

The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases

Contact Info

Product

Resources

About